Drug intelligence / Profile preview

ethinyl estradiol + norgestimate + efavirenz

Development stage
Unknown
Lead developer
Janssen Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Ethinyl estradiol and norgestimate is a combination oral contraceptive containing a synthetic estrogen (ethinyl estradiol) and a progestin (norgestimate), used primarily to prevent pregnancy and also indicated for the treatment of moderate acne in females who desire contraception. The mechanism of action involves suppression of ovulation by inhibiting gonadotropins, thickening cervical mucus to impede sperm penetration, and altering the endometrial lining to reduce the likelihood of implantation. Efavirenz is an antiretroviral drug (non-nucleoside reverse transcriptase inhibitor) used in HIV therapy. When coadministered with ethinyl estradiol/norgestimate, efavirenz significantly reduces plasma concentrations of the progestin component (norgestimate metabolites), potentially decreasing contraceptive efficacy; it does not significantly affect ethinyl estradiol levels. This combination is not recommended for reliable contraception due to this interaction[1][6][8].

Brand names
TriNessa 28TriNessa28TriNessa-28
02

Targets

PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptaseER (Estrogen receptor)

Beyond the preview

Go deeper on ethinyl estradiol + norgestimate + efavirenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinyl estradiol + norgestimate + efavirenz.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call